Moderna & Chiesi Group Establish Collaboration to Discover & Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (P...
September 16 2020 - 4:01PM
Business Wire
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering
messenger RNA (mRNA) therapeutics and vaccines to create a new
generation of transformative medicines for patients and Chiesi
Farmaceutici S.p.A., an international research-focused healthcare
group (Chiesi Group), today announced a collaboration aimed at the
discovery and development of mRNA therapeutics for the treatment of
pulmonary arterial hypertension (PAH), a rare disease with an
incidence of 2-5 per million adults1. PAH is a progressive disorder
characterized by high blood pressure in the arteries of the lungs
with concomitant right heart failure2. There is an unmet medical
need for novel treatments that could delay, or reverse, the disease
progression in patients.
Under the terms of the agreement, Moderna will lead discovery
efforts, leveraging its leading mRNA technology and delivery
platforms along with Chiesi’s expertise in the field of PAH
biology. Chiesi Group will lead development and worldwide
commercialization activities and will fund all expenses related to
the collaboration. Moderna will receive $25 million upfront and is
eligible for more than $400 million in development, regulatory, and
commercial milestones, as well as tiered double-digit royalties on
net sales.
“We are excited to begin this collaboration with Chiesi Group,
which provides the opportunity to further leverage our mRNA and
delivery technology,” said Stephen Hoge, M.D., President of
Moderna. “This new relationship continues our commitment to partner
with companies that have unique expertise in serious diseases, and
who share our vision of using mRNA therapeutics to address the
unmet needs of patients.”
“Chiesi Group is at the forefront of innovation and discovery of
novel therapies for people affected by diseases with high unmet
medical need,” said Ugo Di Francesco, Chief Executive Officer of
Chiesi Group. “The agreement with Moderna, a leader in mRNA science
and delivery, confirms our commitment to better serve patients and
healthcare professionals with transformative solutions.”
About Moderna
Moderna is advancing messenger RNA (mRNA) science to create a
new class of transformative medicines for patients. mRNA medicines
are designed to direct the body’s cells to produce intracellular,
membrane or secreted proteins that can have a therapeutic or
preventive benefit and have the potential to address a broad
spectrum of diseases. Moderna’s platform builds on continuous
advances in basic and applied mRNA science, delivery technology and
manufacturing, providing the Company the capability to pursue in
parallel a robust pipeline of new development candidates. Moderna
is developing therapeutics and vaccines for infectious diseases,
immuno-oncology, rare diseases, cardiovascular diseases, and
autoimmune and inflammatory diseases, independently and with
strategic collaborators.
Headquartered in Cambridge, Mass., Moderna currently has
strategic alliances for development programs with AstraZeneca PLC,
Merck & Co., Inc. and Vertex Pharmaceuticals, Inc. as well as
the Defense Advanced Research Projects Agency (DARPA), an agency of
the U.S. Department of Defense; the Biomedical Advanced Research
and Development Authority (BARDA), a division of the Office of the
Assistant Secretary for Preparedness and Response (ASPR) within the
U.S. Department of Health and Human Services (HHS) and the
Coalition for Epidemic Preparedness Innovations (CEPI). Moderna has
been named a top biopharmaceutical employer by Science for the past
five years. To learn more, visit www.modernatx.com.
About Chiesi Group
Based in Parma, Italy, Chiesi Farmaceutici is an international
research-focused healthcare group with 85 years of experience in
the pharmaceutical industry and a global presence in 29 countries.
Chiesi researches, develops, and markets innovative drugs in the
respiratory therapeutics, specialist medicine, and rare disease
areas. Its R&D organization is headquartered in Parma (Italy),
and is integrated with R&D groups in France, the USA, the UK
and Sweden to advance Chiesi's pre-clinical, clinical and
registration programs. Chiesi employs nearly 6,000 people. Chiesi
Group is a certified Benefit corporation. For more information,
please visit www.chiesi.com.
Moderna’s Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including statements regarding the Company’s
collaboration with Chiesi Farmaceutici to develop and discover mRNA
therapeutics for the treatment of pulmonary arterial hypertension
and the potential commercialization opportunities from such
efforts. In some cases, forward-looking statements can be
identified by terminology such as “will,” “may,” “should,” “could”,
“expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,”
“estimates,” “predicts,” “potential,” “continue,” or the negative
of these terms or other comparable terminology, although not all
forward-looking statements contain these words. The forward-looking
statements in this press release are neither promises nor
guarantees, and you should not place undue reliance on these
forward-looking statements because they involve known and unknown
risks, uncertainties, and other factors, many of which are beyond
Moderna’s control and which could cause actual results to differ
materially from those expressed or implied by these forward-looking
statements. These risks, uncertainties, and other factors include,
among others, the fact that there has never been a commercial
product utilizing mRNA technology approved for use, and those other
risks and uncertainties described under the heading “Risk Factors”
in Moderna’s most recent Quarterly Report on Form 10-Q filed with
the U.S. Securities and Exchange Commission (SEC) and in subsequent
filings made by Moderna with the SEC, which are available on the
SEC’s website at www.sec.gov. Except as required by law, Moderna
disclaims any intention or responsibility for updating or revising
any forward-looking statements contained in this press release in
the event of new information, future developments or otherwise.
These forward-looking statements are based on Moderna’s current
expectations and speak only as of the date hereof.
________________________________ 1 Lancet Resp Medicine, Vol. 4,
issue 4, p. 306-322, 2016 2
https://www.ajmc.com/view/subpopulations-pulmonary-hypertension
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200916005897/en/
Moderna Media: Colleen Hussey Senior Manager, Corporate
Communications 617-335-1374 Colleen.Hussey@modernatx.com Investors:
Lavina Talukdar Head of Investor Relations 617-209-5834
Lavina.Talukdar@modernatx.com Chiesi Group Valentina Biagini
Senior Group Communication Manager Chiesi Group
v.biagini@chiesi.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Apr 2023 to Apr 2024